126 related articles for article (PubMed ID: 10505213)
1. Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension.
Kuwasako K; Kitamura K; Kangawa K; Ishiyama Y; Kato J; Eto T
Ann Clin Biochem; 1999 Sep; 36 ( Pt 5)():622-8. PubMed ID: 10505213
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactive proadrenomedullin N-terminal 20 peptide in human tissue, plasma and urine.
Washimine H; Kitamura K; Ichiki Y; Yamamoto Y; Kangawa K; Matsuo H; Eto T
Biochem Biophys Res Commun; 1994 Jul; 202(2):1081-7. PubMed ID: 8048921
[TBL] [Abstract][Full Text] [Related]
3. Distribution and characterization of rat immunoreactive proadrenomedullin N-terminal 20 peptide (PAMP) and the augmented cardiac PAMP in spontaneously hypertensive rat.
Inatsu H; Sakata J; Shimokubo T; Kitani M; Nishizono M; Washimine H; Kitamura K; Kangawa K; Matsuo H; Eto T
Biochem Mol Biol Int; 1996 Feb; 38(2):365-72. PubMed ID: 8850532
[TBL] [Abstract][Full Text] [Related]
4. Human proadrenomedullin N-terminal 20 peptide in pheochromocytoma and normal adrenal medulla.
Kuwasako K; Kitamura K; Ichiki Y; Kato J; Kangawa K; Matsuo H; Eto T
Biochem Biophys Res Commun; 1995 Jun; 211(2):694-9. PubMed ID: 7794284
[TBL] [Abstract][Full Text] [Related]
5. Distribution and molecular forms of adrenomedullin and proadrenomedullin N-terminal 20 peptide in the porcine gastrointestinal tract.
Kiyomizu A; Kitamura K; Kawamoto M; Eto T
J Gastroenterol; 2001 Jan; 36(1):18-23. PubMed ID: 11211206
[TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of PAMP-12 (PAMP[9-20]) in porcine adrenal medulla as a major endogenous biologically active peptide.
Kuwasako K; Kitamura K; Ishiyama Y; Washimine H; Kato J; Kangawa K; Eto T
FEBS Lett; 1997 Sep; 414(1):105-10. PubMed ID: 9305741
[TBL] [Abstract][Full Text] [Related]
7. Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP).
Kitamura K; Kangawa K; Ishiyama Y; Washimine H; Ichiki Y; Kawamoto M; Minamino N; Matsuo H; Eto T
FEBS Lett; 1994 Aug; 351(1):35-7. PubMed ID: 8076689
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of proadrenomedullin N-terminal 20 peptide and adrenomedullin in patients undergoing hemodialysis.
Tokura T; Kinoshita H; Fujimoto S; Kitamura K; Eto T
Nephron Clin Pract; 2003; 95(2):c67-72. PubMed ID: 14610332
[TBL] [Abstract][Full Text] [Related]
9. Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels.
Etoh T; Kato J; Takenaga M; Imamura T; Kitamura K; Koiwaya Y; Eto T
Clin Cardiol; 1999 Feb; 22(2):113-7. PubMed ID: 10068849
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin and proadrenomedullin N-terminal 20 peptide in impaired renal function.
Eto T; Washimine H; Kato J; Kitamura K; Yamamoto Y
Kidney Int Suppl; 1996 Jun; 55():S148-9. PubMed ID: 8743539
[TBL] [Abstract][Full Text] [Related]
11. [Adrenomedullin and PAMP].
Kitamura K; Eto T
Nihon Rinsho; 1997 Aug; 55(8):1963-70. PubMed ID: 9284408
[TBL] [Abstract][Full Text] [Related]
12. Elevation of circulating proadrenomedullin-N terminal 20-peptide in thyrotoxicosis.
Taniyama M; Kitamura K; Ban Y; Sugita E; Ito K; Katagiri T
Clin Endocrinol (Oxf); 1997 Mar; 46(3):271-4. PubMed ID: 9156034
[TBL] [Abstract][Full Text] [Related]
13. Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans.
Kita T; Kitamura K; Kuwasako K; Kawamoto M; Eto T
J Hypertens; 1998 Dec; 16(12 Pt 2):2057-62. PubMed ID: 9886897
[TBL] [Abstract][Full Text] [Related]
14. Proadrenomedullin N-terminal 20 peptide inhibits aldosterone secretion of human adrenocortical and Conn's adenoma cells: comparison with adrenomedullin effect.
Andreis PG; Tortorella C; Mazzocchi G; Nussdorfer GG
J Clin Endocrinol Metab; 1998 Jan; 83(1):253-7. PubMed ID: 9435451
[TBL] [Abstract][Full Text] [Related]
15. Development of an ultrasensitive enzyme immunoassay for human proadrenomedullin N-terminal 20 peptide and direct measurement of two molecular forms of PAMP in plasma from healthy subjects and patients with cardiovascular disease.
Hashida S; Kitamura K; Nagatomo Y; Shibata Y; Imamura T; Yamada K; Fujimoto S; Kato J; Morishita K; Eto T
Clin Biochem; 2004 Jan; 37(1):14-21. PubMed ID: 14675557
[TBL] [Abstract][Full Text] [Related]
16. Changes of plasma adrenomedullin and proadrenomedullin N-terminal 20 peptide concentrations in patients with heart failure.
Gao YQ; Li ZL; Wu HC; Tang CS; Zhong P; Lu Q; Yan QN
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jul; 22(7):632-4. PubMed ID: 12376296
[TBL] [Abstract][Full Text] [Related]
17. Plasma and urine levels of adrenomedullin and proadrenomedullin N-terminal 20 peptide in chronic glomerulonephritis.
Kinoshita H; Fujimoto S; Kitamura K; Yokota N; Kawamoto M; Tokura T; Hisanaga S; Eto T
Am J Kidney Dis; 1999 Jul; 34(1):114-9. PubMed ID: 10401024
[TBL] [Abstract][Full Text] [Related]
18. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) in adrenal chromaffin cells.
Kobayashi H; Yanagita T; Yokoo H; Wada A
Peptides; 2001 Nov; 22(11):1895-901. PubMed ID: 11754978
[TBL] [Abstract][Full Text] [Related]
19. Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase.
Nagatomo Y; Kitamura K; Kangawa K; Fujimoto Y; Eto T
Biochem Biophys Res Commun; 1996 Jun; 223(3):539-43. PubMed ID: 8687431
[TBL] [Abstract][Full Text] [Related]
20. Adrenomedullin and proadrenomudullin N-terminal 20 peptide (PAMP) are present in human colonic epithelia and exert an antimicrobial effect.
Marutsuka K; Nawa Y; Asada Y; Hara S; Kitamura K; Eto T; Sumiyoshi A
Exp Physiol; 2001 Sep; 86(5):543-5. PubMed ID: 11571480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
